ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth

Key Points

• Renergen has begun Phase 1 helium production in South Africa, with initial customer shipments expected in September and free cash flow targeted by year-end. Phase 2 could significantly expand output, with first production projected for 2030.
• ASP Isotopes is advancing its stable-isotope facilities, with first Silicon-28 and Carbon-14 shipments expected in the second half of the year and Ytterbium-176 production planned later this year.
• The company is pursuing growth in semiconductor materials, medical isotopes and radiopharmaceuticals, while targeting a Quantum Leap Energy spinoff by year-end and $300 million in EBITDA by 2031.

ASP Isotopes NASDAQ: ASPI expects several of its business units to enter commercial production or expand output over the next six months, with Chief Executive Officer Paul Mann highlighting progress in helium, liquefied natural gas, stable isotopes and radiopharmaceuticals during a conference presentation.

Mann said the company’s objective is to strengthen access to critical materials used in electronics, nuclear medicine and nuclear energy. Its operations include PET Labs, stable-isotope enrichment facilities in South Africa, the Renergen helium and energy business, and Quantum Leap Energy, which is focused on fuels including high-assay low-enriched uranium and lithium isotopes.

Helium plant begins production

Renergen was the primary focus of Mann’s presentation. He said the company started its Phase 1 plant in South Africa during the week of the event and expects initial product shipments to customers in September. The plant is expected to begin generating free cash flow by year-end, according to Mann.

The Phase 1 project is expected to produce approximately 70 million cubic feet per day of helium and 2,500 gigajoules per day of LNG. Mann said that, at assumed prices of $600 per thousand cubic feet for helium and $13 to $14 per gigajoule for LNG, the facility could generate roughly $27 million of revenue and $11 million of gross profit. He added that the company was discussing helium prices in the $800 to $1,000 per thousand cubic feet range, while industry participants had indicated spot prices above $2,000 per thousand cubic feet.

Mann said the company expects the Phase 1 facility to reach nameplate capacity by the end of the fourth quarter as additional wells are connected through approximately October.

Phase 2 is planned to be substantially larger, with projected capacity of about 900 million cubic feet per day of liquid helium and 34,000 gigajoules per day of LNG. Mann said the project could generate about $370 million of revenue and $300 million of gross profit using assumed prices of $600 per thousand cubic feet for helium and $14 per gigajoule for LNG.

He said Phase 2 would be supported by approximately $500 million of debt from the U.S. International Development Finance Corporation and about $250 million from Standard Bank. Construction is expected to take about 44 months, with first production anticipated in 2030 and a first full year of output in 2031.

Mann also reiterated the company’s plan, announced in July, to merge the Renergen asset into ENDRA Life Sciences. He said the combined company would be positioned as a NASDAQ-listed helium-focused company.

Stable-isotope facilities progress

ASP Isotopes has built three stable-isotope facilities in South Africa for Silicon-28, Carbon-14 and Ytterbium-176. Mann said all three were being commissioned or prepared for commercial production.

• Silicon-28: The company has assembled the first 48 enrichment stages and is assembling an additional 48 stages. Mann said the plant is currently enriching Silicon-28 and that first shipments are expected in the second half of the year.
• Carbon-14: The facility is currently producing Carbon-12 while awaiting sufficient Carbon-14 feedstock. Mann said commercial Carbon-14 production is expected to begin in the second half.
• Ytterbium-176: The company expects a continuous processing vessel to be completed in September, followed by commercial production later in the year. Mann said the facility could produce approximately one kilogram annually at full utilization.

Addressing prior Silicon-28 delays, Mann said the issue involved compressors supplied by a Swiss manufacturer rather than the enrichment plant’s underlying engineering. He said faulty O-rings prevented the compressors from meeting helium-tight specifications. The company replaced components and now has enough functioning compressors to operate 48 stages, with additional compressor work underway to extend the cascade and reach higher enrichment levels.

Mann said the current plant, at roughly 100 stages, could potentially produce about 80 kilograms annually of Silicon-28 enriched to 99.995%, as well as several hundred kilograms at 99% enrichment. He said a new Silicon-28 plant could be built in about 12 months once construction begins if demand warrants expansion.

Electronics and medical-market opportunities

Mann said Silicon-28 could be used in next-generation semiconductors and quantum-computing applications. He said enrichment to 99% or 99.9% could provide a 20% to 30% thermal-conductivity benefit in chips, while enrichment to 99.995% is expected to be relevant to quantum computing.

The company also plans to supply fluorinated gases, including tungsten hexafluoride and germanium tetrafluoride, to electronics customers. Mann said customers in Asia had expressed interest in securing alternative sources of those materials.

In nuclear medicine, Mann said PET Labs recorded more than 50% revenue growth in the first half of the year and that revenue is expected to double in 2026 compared with 2025. Alpa Theranostics, part of PET Labs, has developed cancer-treatment candidates that Mann said are expected to enter clinical trials later this year.

He also cited growing demand for Ytterbium-176 as Lutetium-177 therapies expand. Mann said Russia is currently the only country capable of enriching Ytterbium-176 in commercial quantities and that customers have described a significant supply shortage.

Quantum Leap Energy spinoff

Mann said ASP Isotopes continues to target a Quantum Leap Energy spinoff by the end of the year, ideally during the third quarter. The company filed an S-1 registration statement in November. He attributed delays in the process partly to an SEC shutdown during the fourth quarter and the need to update financial statements after they became stale in February.

The company’s longer-term goal is to generate $300 million of EBITDA in 2031, Mann said, with potential contributions from electronic gases, helium and LNG, medical isotopes and radiopharmaceuticals.

About ASP Isotopes (NASDAQ:ASPI)

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source